Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma associated with ANCA-associated vasculitis.

Young Hee Rho1, Seong Jae Choi, Young Ho Lee

  • 1Division of Rheumatology, Korea University Anam Hospital, Seoul, South Korea. mania1@hitel.net

Rheumatology International
|July 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.

Pharmacology·2026
Same author

Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2026
Same author

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity.

Pharmacology·2026
Same author

Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence.

Seminars in arthritis and rheumatism·2026
Same author

Efficacy and Safety of Avacopan in ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Controlled Trials.

Pharmacology·2026

Scleroderma patients with anti-topoisomerase antibodies show a higher risk of developing ANCA-associated vasculitis (AAV). This finding suggests a potential role for these antibodies in the development of AAV in scleroderma patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Scleroderma is a complex autoimmune disease.
  • ANCA-associated vasculitis (AAV) is a group of inflammatory disorders.
  • The co-occurrence of scleroderma and AAV is rare but significant.

Purpose of the Study:

  • To investigate the clinical characteristics and risk factors for developing AAV in patients with scleroderma.
  • To analyze the association between specific autoantibodies and the risk of AAV in scleroderma.

Main Methods:

  • Systematic review and statistical analysis of 50 previously reported cases of scleroderma with AAV.
  • Kaplan-Meier survival analysis to compare disease periods and clinical factors.
  • Multivariate Cox regression analysis to identify independent risk factors for AAV development.

Related Experiment Videos

Main Results:

  • Patients with anti-topoisomerase antibody (anti-Scl-70) had a significantly higher risk of developing AAV.
  • PR-3 ANCA positivity may also be associated with an increased risk.
  • Anti-topoisomerase antibody was identified as an independent risk factor for AAV in scleroderma patients (OR 3.1, P=0.031).

Conclusions:

  • Anti-topoisomerase antibodies may play a crucial role in the pathogenesis of AAV among patients with scleroderma.
  • Early identification of anti-topoisomerase antibodies in scleroderma patients could aid in predicting and managing AAV risk.
  • Further research is warranted to elucidate the underlying mechanisms linking these conditions.